GlassScriptPhysician profile
Nicole M Riedy
NPI 1730410762
$2,901.86
in general payments reported to CMS, 2019-2025
32 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $24.38 · 2021: $125 · 2022: $348 · 2023: $789 · 2024: $878 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $463.54 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $276.74 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $230.39 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $229.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $191.61 | 2021-2025 | |
| Axsome Therapeutics, INC. | $162.99 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $137.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $136.00 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $124.61 | 2024-2025 | Voquezna |
| Baxter Healthcare | $116.85 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $84.07 | 2021-2025 | |
| Novo Nordisk INC | $71.63 | 2019-2024 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $64.67 | 2021-2024 | Trintellix |
| Paratek Pharmaceuticals, INC. | $64.57 | 2022-2025 | Nuzyra |
| Currax Pharmaceuticals LLC | $61.20 | 2023-2025 | Contrave, Onzetra Xsail, Nexletol |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $48.73 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $44.36 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $42.66 | 2022-2023 | Unithroid |
| Abbott Laboratories | $42.47 | 2025 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $35.73 | 2024 | Repatha, Otezla |
| Cranial Technologies, INC | $34.82 | 2025 | Doc Band |
| Teva Pharmaceuticals USA, INC. | $31.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.62 | 2022-2023 | Stiolto Respimat |
| Eisai INC. | $27.76 | 2024 | |
| Hikma Pharmaceuticals USA | $26.37 | 2023 | Ryaltris |
| Lundbeck LLC | $21.68 | 2022 | |
| Seqirus USA INC | $20.92 | 2025 | Fluad, Flucelvax |
| Janssen Pharmaceuticals, INC | $20.27 | 2019 | |
| Ibsa Pharma INC. | $19.59 | 2025 | Licart, Flector, Tirosint |
| Amarin Pharma, INC. | $13.88 | 2019 | |
| Kaleo, INC. | $13.84 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.32 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Riedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.